Survival Prediction in Ambulatory Patients With Stage III/IV Non-Small Cell Lung Cancer Using the Palliative Performance Scale, ECOG, and Lung Cancer Symptom Scale

O’Mahony, Sean; Nathan, Susan; Mohajer, Roozbeh; Bonomi, Philip; Batus, Marta; Fidler, Mary J.; Wells, Kalani R.; Kern, Naomi; Sims, Shannon; Amin, Darpan

doi:10.1177/1049909115570707

Cited by 16 publications

(12 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Treatments for late stage are largely palliative and platinum-based chemotherapy regimens have reached a benefit plateau [3]. Regrettably, patients diagnosed at an advanced stage have a life expectancy of <1 year [4].…”

Section: Please Scroll Down For Articlementioning

confidence: 99%

CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer

Ramos

Rodríguez

Vinageras

et al. 2015

Expert Review of Vaccines

View full text Add to dashboard Cite

Epidermal growth factor receptor (EGFR) is overexpressed in many epithelial tumors and its role in the development of non-small-cell lung cancer (NSCLC) is widely documented. CIMAvax-EGF is a therapeutic cancer vaccine composed by recombinant EGF conjugated to a carrier protein and emulsified in Montanide ISA51. Vaccination induces antibodies against self-EGF that block EGF-EGFR interaction and inhibit EGFR phosphorylation. Five clinical trials were conducted to optimize vaccine formulation and schedule. Then, two randomized studies were completed in advanced NSCLC, where CIMAvax-EGF was administered after chemotherapy, as 'switch maintenance'. The vaccine was very well tolerated and the most frequent adverse events consisted of grade 1/2 injection site reactions, fever, headache, vomiting and chills. CIMAvax was immunogenic and EGF concentration was reduced after vaccination. Subjects receiving a minimum of 4 vaccine doses had a significant survival advantage. NSCLC patients with high EGF concentration at baseline had the largest benefit, comparable with best maintenance therapies.

show abstract

Section: Please Scroll Down For Articlementioning

confidence: 99%

CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer

Ramos

Rodríguez

Vinageras

et al. 2015

Expert Review of Vaccines

View full text Add to dashboard Cite

show abstract

“…For example, Maltoni et al 20 reported three categories (PPS 10-20%, PPS 30-50%, PPS ‡60%). Of the 13 studies, the 6 remaining 2,5,12,13,23,24 reported the initial PPS scores as discrete variables, which had different ranges of PPS scores (e.g., PPS 10-70%, PPS 40-90%). Of the six studies, two studies 2,5 reported PPS ranging from 10% to 70%, while the four remaining studies reported various ranges.…”

Section: Pps Scores At Baselinementioning

confidence: 99%

“…Of the six studies, two studies 2,5 reported PPS ranging from 10% to 70%, while the four remaining studies reported various ranges. For example, O'Mahony et al 23 reported PPS scores ranging from 40% to 90%, while Lau et al 11 reported PPS scores ranging from 10% to 80%.…”

Section: Pps Scores At Baselinementioning

confidence: 99%

Using the Palliative Performance Scale to Estimate Survival for Patients at the End of Life: A Systematic Review of the Literature

Baik

Russell

Jordan

et al. 2018

Journal of Palliative Medicine

View full text Add to dashboard Cite

show abstract

“…Among them, the Lung Cancer Symptom Scale consists of a lung cancer-specific measure of QoL. This scale is used particularly in clinical trials and assesses six common symptoms associated with lung cancer, such as loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain 55. This evaluation involves the use of the visual analog scale.…”

Section: Impact Of Patient-focused Perspectives Such As Qolmentioning

confidence: 99%

Potential role of immunotherapy in advanced non-small-cell lung cancer

Mello

Veloso

Catarina

et al. 2016

OTT

View full text Add to dashboard Cite

Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib, erlotinib, and afatinib) or with anaplastic lymphoma kinase inhibitors (eg, crizotinib and ceritinib). As a result, anti-PD-1/PD-L1 and CTLA-4 inhibitors may play a novel role in the improvement of outcomes in a metastatic setting. The regulation of immune surveillance, immunoediting, and immunoescape mechanisms may play an interesting role in this regard either alone or in combination with current drugs. Here, we discuss advances in immunotherapy for the treatment of metastatic non-small-cell lung cancer as well as future perspectives within this framework.

show abstract

Survival Prediction in Ambulatory Patients With Stage III/IV Non-Small Cell Lung Cancer Using the Palliative Performance Scale, ECOG, and Lung Cancer Symptom Scale

Abstract: The LCSS predicted prognosis best in this study. The PPS did not accurately predict prognosis in our patient population.

Cited by 16 publications

References 26 publications

CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer

CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer

Using the Palliative Performance Scale to Estimate Survival for Patients at the End of Life: A Systematic Review of the Literature

Potential role of immunotherapy in advanced non-small-cell lung cancer

Contact Info

Product

Resources

About